377 related articles for article (PubMed ID: 31919793)
1. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
[TBL] [Abstract][Full Text] [Related]
2. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
3. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
5. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
7. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
8. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
9. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
10. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
11. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
12. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
13. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
Povsic M; Wong OY; Perry R; Bottomley J
Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
[TBL] [Abstract][Full Text] [Related]
15. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
[TBL] [Abstract][Full Text] [Related]
16. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.
Tampi RP; Wong VW; Wong GL; Shu SS; Chan HL; Fung J; Stepanova M; Younossi ZM
Hepatol Res; 2020 Sep; 50(9):1024-1031. PubMed ID: 32537840
[TBL] [Abstract][Full Text] [Related]
17. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
Vernon G; Baranova A; Younossi ZM
Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
[TBL] [Abstract][Full Text] [Related]
19. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.
Younossi ZM; Tampi R; Priyadarshini M; Nader F; Younossi IM; Racila A
Hepatology; 2019 Feb; 69(2):564-572. PubMed ID: 30180285
[TBL] [Abstract][Full Text] [Related]
20. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
